Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will announce its financial results for Q4 and full year 2022 on February 22, 2023, after market close. The management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been commercially available in over 25 countries and used to treat more than 25,000 patients.

Investors can access a live and archived webcast of the event on the Investors section of the Pulmonx website.

Positive

• Received FDA pre-market approval for the Zephyr Valve, recognized as a 'breakthrough device.'
• The Zephyr Valve is commercially available in over 25 countries.
• More than 100,000 valves have been used to treat over 25,000 patients.

Negative

• None.

REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When will Pulmonx release its financial results for 2022?

Pulmonx will release its financial results on February 22, 2023, after market close.

What time is the conference call for Pulmonx's financial results?

The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET.

What products does Pulmonx offer?

Pulmonx offers the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform.

How many countries have approved the Zephyr Valve?

The Zephyr Valve is commercially available in over 25 countries.

How many patients have been treated with the Zephyr Valve?

Over 25,000 patients have been treated with the Zephyr Valve.